The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Exciting myeloma updates coming soon at EHA 2021
Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, shares what he’s looking forward to at the virtual European Hematology Association (EHA) Congress 2021, in particular highlighting updates on new combinations in the frontline setting for multiple myeloma, and novel data on bispecific antibodies, antibody-drug conjugates and chimeric antigen receptor T-cell (CAR-T) therapy.
Disclosures
Enrique M. Ocio, MD, PhD has received honoraria or consultancy fees from Janssen, BMS, Sanofi, GSK, Oncopeptides, Amgen, Takeda, Secura-Bio, MSD and Mundipharma-EDO.
